Remove

Under the Paperwork Reduction Act of 1995, no persons are required o a collection of information unless it contains a valid OMB control number.

U.S. PATENTS

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10709382		
Filing Date		2004-04-30		
First Named Inventor Micha		nel P. Schoemann		
Art Unit		3612		
Examiner Name	Kiran	B. Patel		
Attorney Docket Number		MAS-37		

Examiner Initial*	miner Cite No Patent Number Kind Code <sup>1</sup> Issue Date Name of Patentee or Appl of cited Document			Releva	Columns,Lines whe int Passages or Rele s Appear	re vant				
	1	5651998 1997-07-29 Bertschi et al.								
	2	6322738		2001-11	1-27	Sicilia et al.				
	3	6572300		2003-06	<b>∔03</b>	Altonen et al.				
If you wisi	h to ac	dd additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLIC	CATION PUBL	<b>JCATIONS</b>		Remove	
Examiner Cite Initial* Publication Number Kind Code1				nd Publication Name of Patentee or Applicant of cited Document				Releva	Columns,Lines whe int Passages or Rele s Appear	
	1									
If you wish	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Ad	d button	Add	
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove	
Examiner Cite   Foreign Document   Country   Initial*   No   Number3   Code2				Publication Date Name of Patente Applicant of cited Document		e or	Pages,Columns,Line where Relevant Passages or Relevar Figures Appear	Ts		
	1									
EEP WILL 2.0										

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10709382		
Filing Date		2004-04-30		
First Named Inventor	Micha	Michael P. Schoemann		
Art Unit		3612		
Examiner Name	Kıran B. Patel			
Attorney Docket Numb	or	MAS.37		

If you wis	n to a	dd addi	ional Foreig	n Patent L	ocument	citation i	nformatio	n please	click the Add	butto				
				NC	N-PATE	NT LITER	RATURE	DOCUM	IENTS		Remov	e		
Examiner Initials*	Cite No	(book,	magazine,	name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), er, city and/or country where published.								Ţ5		
	1		AWRENCE EMILE LAMBELET (EXAMINER): Office Action issued in a related patient application Serial No. 10/708,312; dated as mailed on September 18, 2006; 12 pages; U.S. Patent and Trademark Office.											
	2		LICIA ANN CHEVALIER (EXAMINER); Office Action issued in a related patent application Serial No. 10/708,315; sted as mailed on October 5, 2006; 11 pages; U.S. Patent and Trademark Office.											
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add													
					EX	AMINER	SIGNAT	URE						
Examiner	Signs	ture							Date Consid	ered				

F

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04, 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language translation is attached.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

	Application Number		10709382	
	Filing Date		2004-04-30	
	First Named Inventor	Micha	el P. Schoemann	
	Art Unit		3612	
	Examiner Name	Kıran	B. Patel	
	Attorney Docket Number		MAS-37	

#### CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98	to make the ag	propriate selection(s):
---------------	----------	----------	----------------	-------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

#### OR

That no item of information contained in the information disclosure statement was cited in a communication from a deeping patient office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to a not individual designated in 37 CFR 1.58(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.57(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ....

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Steven W. Benintendi/	Date (YYYY-MM-DD)	2006-10-25
Name/Print	Steven W. Renintendi	Registration Number	56.297

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1445, Alexandrin, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandria, V.S. 2311-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.